First-in-human Trial With Single-dose C5a-neutralizing AON-D21 in Healthy Male Subjects
Study Details
Study Description
Brief Summary
The main purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamic parameters after single ascending intravenous doses of AON-D21 in healthy male subjects.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
This study will potentially include 5 sequential cohorts with 8 subjects per cohort, then 40 enrolled subjects in total. Within each dose group 6 subjects will be randomized to receive AON-D21 and 2 subjects will be randomly assigned to placebo.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: AON-D21 Single ascending doses by iv infusion. |
Drug: Intravenous AON-D21
AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
Other Names:
|
| Placebo Comparator: Placebo Placebo medication identical in appearance to active. |
Drug: Intravenous placebo
Isotonic glucose solution identical in appearance to AON-D21.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Primary Safety Endpoint - Overall number of participants with treatment-emergent adverse events (TEAEs) per dosing cohort as assessed by CTCAE. [14 days.]
To determine the overall safety and tolerability of AON-D21 by analyzing number of participants with treatment-related adverse events as assessed by CTCAE. Nature, occurrence, and severity of treatment-emergent adverse events.
- Primary Safety Endpoint - Per Dosing Cohort number of participants with treatment-emergent adverse events as assessed by CTCAE. [14 days]
Overall number of participants with treatment related treatment-emergent adverse events (TEAEs) as assessed by CTCAE per dosing cohort.
Secondary Outcome Measures
- Pharmacokinetics of AON-D21. [14 days.]
To determine the area under the concentration (AUC)-time curve from 0 to 48 h (AUC0-48).
- Pharmacokinetics of AON-D21. [14 days.]
To determine the area under the concentration (AUC)-time curve from 0 to 72 h (AUC0-72).
- Pharmacokinetics of AON-D21. [14 days.]
To determine the area under the concentration (AUC)-time curve from 0 to infinity (AUC0-inf).
- Pharmacokinetics of AON-D21. [14 days.]
To determine the maximum concentration (Cmax).
- Pharmacokinetics of AON-D21. [14 days.]
To determine the time of maximum concentration (Tmax).
- Pharmacokinetics of AON-D21. [14 days.]
To determine the half-life (t1/2).
- Pharmacokinetics of AON-D21. [14 days.]
To determine the plasma clearance (CL) calculated as Dose/AUC0-inf.
- Pharmacokinetics of AON-D21. [14 days.]
To determine the volume of distribution (Vz).
- Pharmacokinetics of AON-D21. [14 days.]
To determine the amount of AON-D21 excreted (Ae) in urine.
- Pharmacokinetics of AON-D21. [14 days.]
To determine the renal clearance (CLR) of AON-D21.
Other Outcome Measures
- Pharmacodynamics [14 days]
To determine the C5a inhibition capacity of AON-D21 by measuring active C5a in blood using a cell-based assay.
- Effects on the complement status [14 days]
Determining the effect of AON-D21 on levels of C5, C5a, C5b-9 in blood and on the capacity of terminal complement complex formation.
- To assess potential for immunogenicity of AON-D21 [14 days]
Determining the presence of anti-drug antibodies (ADA) and anti-peg antibodies in serum.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18 to 55 years of age inclusive, at the time of signing the informed consent.
-
Body mass index (BMI) within the range 18 - 30 kg/m2 with a body weight between 50 kg and 120 kg.
-
Male subjects
-
Subject is healthy as determined by medical evaluation
-
Subject provided written informed consent
-
Subject is willing to comply with all requirements and restrictions according to the study protocol.
Exclusion Criteria:
-
Any concomitant disease, condition, or treatment that could interfere with the conduct of the study.
-
Any acquired or congenital immune deficiency.
-
Acute infection (including viral infections) in the preceding 6 weeks (8 weeks for respiratory infections).
-
Any concomitant disease, condition, or treatment that could interfere with the conduct of the study.
-
Any acquired or congenital immune deficiency.
-
Acute infection (including viral infections) in the preceding 6 weeks (8 weeks for respiratory infections).
-
Clinically relevant abnormality following the Investigator's review of the physical examination, vital signs, ECG and clinical study protocol-defined clinical laboratory tests that, in the opinion of the Investigator, would preclude inclusion in the trial at screening and admission.
-
Evidence of COVID-19 signs or symptoms, exposure to infected person or confirmed COVID-19 infection within the last 2 weeks.
-
Use of any concomitant medication or prescribed or non-prescribed drugs within 2 weeks or 5 times the half-life, whichever is longer, prior to the first study treatment administration.
-
Administration of vaccine(s) within 2 weeks prior to screening or plans to receive such vaccines during the study.
-
Use of any investigational drug or participation in any clinical study within 30 days or 5 half-life times, whichever is longer, prior to dosing.
-
Positive drug or alcohol screen at screening and admission.
-
Any significant blood loss, donated one unit (450 mL) of blood or more, or donated plasma, or received a transfusion of any blood or blood products within 30 days prior to dosing.
-
Subjects who are unable to refrain from the consumption of Seville oranges, grapefruit or grapefruit juice and /or pomelos, exotic citrus fruits, grapefruit hybrids, starfruit or fruit juices from 72 hours prior to dosing on Day 1, until completion of the last pharmacokinetic (PK) blood sample time point.
-
Legal incapacity or limited legal capacity, or incarceration.
-
Inability to understand or communicate reliably with the Investigator.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Nuvisan GmbH | Neu-Ulm | Germany | 89231 |
Sponsors and Collaborators
- Aptarion Biotech AG
Investigators
- Principal Investigator: Manuela Koch, MD, Nuvisan GmbH
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- S-D21-C100
- 2021-000935-30